Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Bought by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd raised its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 287.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 27,061 shares of the company’s stock after purchasing an additional 20,070 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Harmony Biosciences were worth $931,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. boosted its position in Harmony Biosciences by 21.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,056 shares of the company’s stock valued at $80,000 after buying an additional 360 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Harmony Biosciences by 92.6% in the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock valued at $31,000 after acquiring an additional 436 shares during the last quarter. New York State Teachers Retirement System boosted its holdings in shares of Harmony Biosciences by 2.6% in the 4th quarter. New York State Teachers Retirement System now owns 31,693 shares of the company’s stock valued at $1,091,000 after acquiring an additional 809 shares during the last quarter. KBC Group NV increased its stake in shares of Harmony Biosciences by 79.9% in the fourth quarter. KBC Group NV now owns 1,844 shares of the company’s stock worth $63,000 after acquiring an additional 819 shares during the period. Finally, Hedeker Wealth LLC raised its holdings in shares of Harmony Biosciences by 1.2% during the fourth quarter. Hedeker Wealth LLC now owns 76,203 shares of the company’s stock worth $2,622,000 after purchasing an additional 916 shares during the last quarter. 86.23% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Harmony Biosciences

In related news, insider Jeffrey Dierks sold 10,507 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $37.01, for a total transaction of $388,864.07. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Sandip Kapadia sold 1,775 shares of the firm’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $38.05, for a total value of $67,538.75. The disclosure for this sale can be found here. Insiders sold 72,452 shares of company stock valued at $2,831,679 over the last quarter. 30.80% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts have commented on HRMY shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $50.00 price target on shares of Harmony Biosciences in a report on Tuesday. Deutsche Bank Aktiengesellschaft started coverage on Harmony Biosciences in a research note on Tuesday, February 11th. They issued a “buy” rating and a $55.00 target price on the stock. Mizuho reduced their price target on Harmony Biosciences from $52.00 to $42.00 and set an “outperform” rating for the company in a research report on Thursday, February 20th. Finally, HC Wainwright decreased their target price on shares of Harmony Biosciences from $75.00 to $70.00 and set a “buy” rating for the company in a research note on Thursday. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $53.11.

Harmony Biosciences Price Performance

Shares of NASDAQ HRMY opened at $32.75 on Friday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. The firm has a fifty day moving average of $36.66 and a 200 day moving average of $35.81. The firm has a market cap of $1.87 billion, a PE ratio of 15.52, a PEG ratio of 0.47 and a beta of 0.80. Harmony Biosciences Holdings, Inc. has a one year low of $28.14 and a one year high of $41.61.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings results on Tuesday, February 25th. The company reported $0.85 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.11. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The firm had revenue of $201.30 million during the quarter, compared to the consensus estimate of $201.25 million. During the same quarter in the prior year, the firm earned $0.45 EPS. The company’s revenue for the quarter was up 19.5% on a year-over-year basis. As a group, research analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.